---
title: "ARTH.US (ARTH.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/ARTH.US/news.md"
symbol: "ARTH.US"
name: "ARTH.US"
parent: "https://longbridge.com/zh-CN/quote/ARTH.US.md"
datetime: "2026-03-15T17:47:32.164Z"
locales:
  - [en](https://longbridge.com/en/quote/ARTH.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARTH.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARTH.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/ARTH.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ARTH.US/news.md)


# ARTH.US (ARTH.US) — 相关新闻

### [Arthrex Releases TightRope® SB All-Suture Implant for ACL Fixation](https://longbridge.com/zh-CN/news/277081966.md)
*2026-02-26T18:10:44.000Z*
> Arthrex has launched the TightRope® SB implant, the first all-suture device for ACL reconstruction, enhancing minimally 

### [Arthex Biotech's ATX-01 promising for DM1 per American Journal of Human Genetics; miR-23b target shows benefits.](https://longbridge.com/zh-CN/news/276854985.md)
*2026-02-25T08:03:29.000Z*
> New findings suggest that miR-23b could be a crucial target in treating DM1, with research revealing its disease-modifyi

### [Arch Biopartners posts FY net loss of USD 1.6 million and cash flow from financing activities of USD 1.6 million](https://longbridge.com/zh-CN/news/274092693.md)
*2026-01-29T05:10:25.000Z*
### [Arch Therapeutics : Material Agreement - Form 8-K](https://longbridge.com/zh-CN/news/82689805.md)
*2023-03-17T10:08:26.000Z*
> (marketscreener.com) arch20230315_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-